PharmaEssentia Corporation (8Z1.F)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Dr. Ching-Leou Teng Ph.D. | Chairman & Chief Pharmaceutical Officer | 263.99k | -- | -- |
| Mr. Ko-Chung Lin Ph.D. | Founder, CEO, Chief Strategy Officer & Director | 291.88k | -- | -- |
| Mr. Chan-Kou Hwang | Pres, GM & Director | 263.99k | -- | -- |
| Ms. Snow Chang | Accounting Mang. & Sr. Mang. of Fin. | -- | -- | -- |
| Mr. Samuel Lin | VP and Head of Bus. Operations & Strategy | -- | -- | -- |
| Ms. Lih-Ling Lin Ph.D. | Chief Scientific Officer | -- | -- | -- |
| Ms. Rachel Lipsitz | VP and Head of Corp. Communications & Advocacy | -- | -- | -- |
| Mr. Roddy Mcilwain | Sr. VP and Head of Sales & Marketing | -- | -- | -- |
| Ms. Anjana Pursnani | Sr. VP & Head of People | -- | -- | -- |
| Dr. Albert Qin M.D., Ph.D. | Chief Medical Officer | -- | -- | -- |
PharmaEssentia Corporation
- Sector:
- Healthcare
- Industry: Drug Manufacturers - Specialty & Generic
Description
PharmaEssentia Corporation, a biopharmaceutical company engages in treatment for human diseases in Taiwan and internationally. Its products include BESREMi (ropeginterferon alfa-2b) that is used for the treatment of chronic myelogenous leukemia, T-Cell leukemia, primary myelofibrosis, polycythemia vera, and essential thrombocythemia. The company licensed to develop Oraxol for the treatment of breast, gastric, gastro-esophageal, and esophageal cancer; and KX01 for the treatment of psoriasis. In addition, it focuses on the drug research and development programs in the areas of hematology, infectious disease, oncology, and dermatology. PharmaEssentia Corporation was founded in 1990 and is headquartered in Taipei, Taiwan.
Corporate Governance
Upcoming Events
August 11, 2025 at 10:59 AM UTC - August 15, 2025 at 12:00 PM UTC
PharmaEssentia Corporation Earnings Date
Recent Events
Recent Events Information Not Available